Results 11 to 20 of about 253,061 (341)
Current Biology, 2002 Yes! One of the earliest observations indicating the therapeutic importance of mTOR involved the immunosuppressive effects of its inhibitor, rapamycin. Indeed, a form of rapamycin (Rapammune®) is on the market for use in organ transplantation. Recently, Phase I clinical trials were completed in which another form of rapamycin (CCI-779) was tested in ...
Patrick B. Dennis, George Thomas
openaire +2 more sources
Longevity, aging and rapamycin [PDF]
Cellular and Molecular Life Sciences, 2014 The federal drug administration (FDA)-approved compound rapamycin was the first pharmacological agent shown to extend maximal lifespan in both genders in a mammalian species. A major question then is whether the drug slows mammalian aging or if it has isolated effects on longevity by suppressing cancers, the main cause of death in many mouse strains ...
Ehninger, D., Neff, F., Xie, K.
openaire +4 more sources
Conditional U1 gene silencing in Toxoplasma gondii [PDF]
, 2015 The functional characterisation of essential genes in apicomplexan parasites, such as Toxoplasma gondii or Plasmodium falciparum, relies on conditional mutagenesis systems. Here we present a novel strategy based on U1 snRNP-mediated gene silencing.
Blackman, Michael J. +10 more
core +8 more sources
Molecular Basis of the Rapamycin Insensitivity of Target Of Rapamycin Complex 2 [PDF]
Molecular Cell, 2015 Target of Rapamycin (TOR) plays central roles in the regulation of eukaryote growth as the hub of two essential multiprotein complexes: TORC1, which is rapamycin-sensitive, and the lesser characterized TORC2, which is not. TORC2 is a key regulator of lipid biosynthesis and Akt-mediated survival signaling.
Sandra Eltschinger +15 more
openaire +5 more sources
Inhibition of MDM2 Re-Sensitizes Rapamycin Resistant Renal Cancer Cells via the Activation of p53
Cellular Physiology and Biochemistry, 2016 Background/Aims: Rapamycin is a potential anti-cancer agent, which modulates the activity of mTOR, a key regulator of cell growth and proliferation. However, several types of cancer cells are resistant to the anti-proliferative effects of rapamycin.
Xin Tian +11 more
doaj +1 more source
Frontiers in Genetics, 2020 DNA methylation is an indispensable epigenetic modification that dynamically regulates gene expression and genome stability during cell growth and development processes.
Tingting Zhu +7 more
doaj +1 more source
Rapamycin induces transactivation of the EGFR and increases cell survival. [PDF]
, 2009 The mammalian target of rapamycin (mTOR) signaling network regulates cell growth, proliferation and cell survival. Deregulated activation of this pathway is a common event in diverse human diseases such as cancers, cardiac hypertrophy, vascular ...
Chaturvedi, D +4 more
core +2 more sources
Probing the environment of emerin by Enhanced ascorbate peroxidase 2 (APEX2)-mediated proximity labeling. [PDF]
, 2020 Emerin is one of the best characterized proteins of the inner nuclear membrane, but can also occur at the level of the endoplasmic reticulum. We now use enhanced ascorbate peroxidase 2 (APEX2) to probe the environment of emerin.
James, C. +4 more
core +1 more source
Frontiers in Genetics, 2013 The mammalian target of rapamycin (mTOR) inhibitors, a set of promising potential anti-cancer agents, has shown response variability among individuals.
Jing eJiang +8 more
doaj +1 more source